Research Fellows
Soon Gang Choi
Research Fellow
education
PhD, Mount Sinai School of Medicine 2012
M.S., University of Michigan, Ann Arbor 2006
B.S., Illinois Institute of Technology 2004
contact Info
SoonG_Choi@dfci.harvard.edu
I study how protein-protein interactions (PPIs) can be targeted by small molecule drugs. One of major bottlenecks for developing PPI drugs is the lack of robust high-throughput technologies that can systemically identify drug-like compounds against PPIs in human proteome, given the fact that there are a large numbers of PPIs in the human proteome (~600,000 estimate) and vast chemical space for small molecules. To this end, I’ve been developing and employing state-of-art PPI technologies including Nanoluc-two-hybrid, DNA-barcoded PPI assay, and reverse yeast two-hybrid that can measure the formation and disruption of PPIs by compounds in high-throughput fashions with high sensitivity. Attaining the ability to specifically modulate PPIs by small molecules will help us to develop novel drugs for various human diseases including cancers and will lead to deeper understanding of human protein interactome network.
Research Fellow
education
PhD, Mount Sinai School of Medicine 2012
M.S., University of Michigan, Ann Arbor 2006
B.S., Illinois Institute of Technology 2004
contact Info
SoonG_Choi@dfci.harvard.edu
I study how protein-protein interactions (PPIs) can be targeted by small molecule drugs. One of major bottlenecks for developing PPI drugs is the lack of robust high-throughput technologies that can systemically identify drug-like compounds against PPIs in human proteome, given the fact that there are a large numbers of PPIs in the human proteome (~600,000 estimate) and vast chemical space for small molecules. To this end, I’ve been developing and employing state-of-art PPI technologies including Nanoluc-two-hybrid, DNA-barcoded PPI assay, and reverse yeast two-hybrid that can measure the formation and disruption of PPIs by compounds in high-throughput fashions with high sensitivity. Attaining the ability to specifically modulate PPIs by small molecules will help us to develop novel drugs for various human diseases including cancers and will lead to deeper understanding of human protein interactome network.
Anupama Yadav
Research Fellow
education
PhD, Tata Institute of Fundamental Research 2016
B.S., University of Delhi 2010
contact Info
Anupama_Yadav@dfci.harvard.edu
Having lived in multiple locations in the culturally and geographically diverse India, variation has been a constant presence in my life. Traveling to different continents simply emphasized the abundance of this variation. In my Ph.D., I studied the genetic regulation of this high phenotypic diversity in ecologically and geographically diverse yeast populations, and identified gene-gene and gene-environment interactions which contribute to their robustness and plasticity.
As an academic, I am interested in applying evolutionary concepts and tools to better understand the genotype-phenotype map and address questions of current relevance. Specifically, I am interested in understanding how the vast genetic diversity present in human populations modifies the molecular interactome, and utilize this information to study long standing questions of incomplete penetrance of variants, differential susceptibility to infections, differential sensitivity to therapeutics etc.
Research Fellow
education
PhD, Tata Institute of Fundamental Research 2016
B.S., University of Delhi 2010
contact Info
Anupama_Yadav@dfci.harvard.edu
Having lived in multiple locations in the culturally and geographically diverse India, variation has been a constant presence in my life. Traveling to different continents simply emphasized the abundance of this variation. In my Ph.D., I studied the genetic regulation of this high phenotypic diversity in ecologically and geographically diverse yeast populations, and identified gene-gene and gene-environment interactions which contribute to their robustness and plasticity.
As an academic, I am interested in applying evolutionary concepts and tools to better understand the genotype-phenotype map and address questions of current relevance. Specifically, I am interested in understanding how the vast genetic diversity present in human populations modifies the molecular interactome, and utilize this information to study long standing questions of incomplete penetrance of variants, differential susceptibility to infections, differential sensitivity to therapeutics etc.
Luke Lambourne
Research Fellow
education
PhD, University College London 2014
M.Phys., University of Warwick 2010
contact Info
luke_lambourne@dfci.harvard.edu
I’m a computational biologist, interested using the huge amount of information generated by high-throughput systematic protein-level experiments in order to answer biological questions. I build custom statistical models based on details of the experiment in order to disentangle the variety of different factors that underlie the data. Currently, I’m working on the human reference interactome project, where I’m modeling the variance of confidence and ease of detection of interactions within the dataset.
Research Fellow
education
PhD, University College London 2014
M.Phys., University of Warwick 2010
contact Info
luke_lambourne@dfci.harvard.edu
I’m a computational biologist, interested using the huge amount of information generated by high-throughput systematic protein-level experiments in order to answer biological questions. I build custom statistical models based on details of the experiment in order to disentangle the variety of different factors that underlie the data. Currently, I’m working on the human reference interactome project, where I’m modeling the variance of confidence and ease of detection of interactions within the dataset.